Titan Pharmaceuticals, Inc. (TTNP) P/E Ratio History
Deep ValueTrading at -0.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1997–2017
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Titan Pharmaceuticals, Inc. (TTNP) trades at a price-to-earnings ratio of -0.6x, with a stock price of $3.08 and trailing twelve-month earnings per share of $-2.63.
The current P/E is 100% below its 5-year average of 966.4x. Over the past five years, TTNP's P/E has ranged from a low of 106.5x to a high of 7528.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, TTNP trades at a 103% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, TTNP trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TTNP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TTNP Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TTNP P/E vs Peers
Drug Delivery Technology Platforms peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $383M | 43.6 | - | -43% | |
| $164M | 2.7Lowest | - | +419% | |
| $1B | 19.3 | 1.08Best | -7% | |
| $1B | 194.5 | - | -79% | |
| $407B | 97.1 | - | -1% | |
| $1B | 26.1 | 3.58 | +1883%Best | |
| $893M | 141.9 | - | +107% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TTNP Historical P/E Data (1997–2017)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2017 Q1 | Mar 31 2017 | $11880.00 | $31.85 | 373.0x | -61% |
| FY2016 Q4 | Dec 31 2016 | $14400.00 | $40.86 | 352.4x | -64% |
| FY2016 Q3 | Sep 30 2016 | $21168.00 | $40.22 | 526.3x | -46% |
| FY2016 Q2 | - | $19692.00 | $46.26 | 425.7x | -56% |
| FY2014 Q1 | Mar 31 2014 | $13325.97 | $24.59 | 541.9x | -44% |
| FY2013 Q4 | - | $12132.60 | $113.97 | 106.5x | -89% |
| FY2013 Q3 | Sep 30 2013 | $13325.97 | $113.12 | 117.8x | -88% |
| FY2013 Q2 | Jun 30 2013 | $9149.17 | $8.16 | 1121.2x | +16% |
| FY1998 Q3 | Sep 30 1998 | $60911.60 | $440.55 | 138.3x | -86% |
| FY1998 Q2 | - | $91988.95 | $361.35 | 254.6x | -74% |
| FY1998 Q1 | - | $93232.05 | $846.45 | 110.1x | -89% |
| FY1997 Q4 | Dec 31 1997 | $111878.45 | $14.86 | 7528.8x | +679% |
Average P/E for displayed period: 966.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
29+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TTNP — Frequently Asked Questions
Quick answers to the most common questions about buying TTNP stock.
What is TTNP's P/E ratio?
Titan Pharmaceuticals, Inc. (TTNP) trailing twelve-month P/E ratio is -0.6x, based on TTM diluted EPS of $-2.63. The 5-year average P/E is 966.4x and the historical range spans 106.5x to 7528.8x.
Is TTNP stock overvalued or undervalued?
TTNP trades at -0.6x P/E, below its 5-year average of 966.4x. At the 0th percentile of its historical range (106.5x–7528.8x), the stock is priced at a discount to its own history.
Is TTNP stock expensive?
No, TTNP is not expensive on a historical basis. The current P/E of -0.6x is below the 5-year average of 966.4x and sits at the 0th percentile of its valuation range.
What is TTNP's historical P/E range?
Over the past 5 years, TTNP's P/E ratio has ranged from 106.5x to 7528.8x, with a median of 373.0x and an average of 966.4x. The current P/E of -0.6x places the stock at the 0th percentile of this range. Full historical data spans 1997–2017.
How does TTNP's P/E compare to the S&P 500?
TTNP trades at -0.6x P/E versus the S&P 500 median of 24.3x. The 102% discount to the market suggests lower growth expectations or perceived higher risk.
How does TTNP's valuation compare to Healthcare peers?
Titan Pharmaceuticals, Inc. P/E of -0.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TTNP's PEG ratio?
TTNP PEG ratio is N/A, based on a P/E of -0.6x and EPS growth of 29.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TTNP's earnings yield?
TTNP earnings yield is N/A, the inverse of its -0.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.